12.01 0.00 (0.00%)
After hours: 4:25PM EDT
|Bid||12.03 x 2200|
|Ask||12.45 x 1400|
|Day's Range||11.99 - 12.32|
|52 Week Range||5.18 - 14.90|
|Beta (3Y Monthly)||1.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.40|
SOUTH SAN FRANCISCO, Calif., June 20, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive.
Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will introduce three new Imaging Mass Cytometry™ Maxpar® panel kits and an advanced CyTOF® software solution in the third quarter to power immuno-oncology research. Imaging Mass Cytometry is rapidly advancing our understanding of health and disease by empowering researchers around the globe to deeply profile cellular phenotypes in tumors and tissues. The new ready-to-go Maxpar panel kits for immuno-oncology studies can enable researchers to rapidly profile immune infiltrates across a range of human cancer types and treatment modalities with Imaging Mass Cytometry.
Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will introduce seven new cadmium metal labeling kits for mass cytometry in Q3. Representing the first of a series of new metal isotopes in development, these new isotopes will empower researchers to easily design and customize larger panels to advance biomarker discovery and therapeutic development. Mass cytometry is an industry-leading tool for deep interrogation of cellular phenotypes and function in health and disease.
Quong will lead the company’s strategy for the generation of bold scientific insights in immunology, immuno-oncology and other frontiers of human health based on Fluidigm® technology. Quong was most recently Director of Strategic Scientific Initiatives and Partnerships at the Frederick National Laboratory for Cancer Research, a federally funded research and development center sponsored by the National Cancer Institute.
Fluidigm Corporation (FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of May 31, 2019, under Fluidigm’s 2017 Inducement Award Plan (“Plan”), as a material inducement to employment to an individual hired by Fluidigm in May 2019. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today introduced the Advanta™ RNA Fusions NGS Library Prep Assay for detection of over 380 gene fusion pairs from solid tumors and hematological cancers. Developed to fuel new advances in translational and clinical cancer research, the assay uniquely empowers researchers to interrogate gene fusions from a wide range of cancer types using a simple and highly efficient automated NGS library prep workflow.
SOUTH SAN FRANCISCO, Calif., May 29, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive.
Before we spend countless hours researching a company, we'd like to analyze what insiders, hedge funds and billionaire investors think of the stock first. We would like to do so because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors […]
Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor conferences. Chris Linthwaite, President and Chief Executive Officer, will participate in a fireside chat regarding Fluidigm’s business strategy and financial performance on Tuesday, May 21, 2019 at 11:30 ET at the UBS Global Healthcare Conference in New York. Vikram Jog, Chief Financial Officer, is scheduled to present on Tuesday, June 4, 2019, at 1:30 pm ET regarding Fluidigm’s business strategy and financial performance at the Jefferies 2019 Healthcare Conference in New York.
The decision to retire $150 million in convertible debt caught the market off guard, but the business made progress on its long-term goals.
Fluidigm (FLDM) delivered earnings and revenue surprises of -40.00% and 4.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The South San Francisco, California-based company said it had a loss of 44 cents per share. Losses, adjusted for one-time gains and costs, came to 14 cents per share. The company that makes equipment to ...
First quarter revenue increased 19 percent to $30.1 million Mass cytometry revenue growth of 110 percent in first quarter Strong mass cytometry and Imaging Mass Cytometry.
Fluidigm Corporation (FLDM) announced today that the Group for Innovative Cancer Treatment Division of the National Cancer Center in Japan has expanded its clinical research in colorectal cancer using the Hyperion™ Imaging System to study regulatory T (Treg) cell proliferation in tumor tissue with the goal of discovering a novel target for immunotherapy.
Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.
Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will hold the 8th Annual Fluidigm Mass Cytometry Summit on June 20 and 21, 2019, at the Pinnacle Hotel Harbourfront in Vancouver, Canada. The Summit brings together translational researchers from around the world to discuss new mass cytometry research applications and best practices for identifying biomarker signatures in health and disease and accelerating therapeutic development. “We are excited to hold this year’s Summit right before CYTO® 2019,” said Chris Linthwaite, President and CEO of Fluidigm.
Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.
Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In 2016 Chris Linthwaite was appointed CEO of Fluidigm Corporation (NASDAQ:FLDM). This report will, first, examine...